YSCH-01 is under clinical development by Shanghai Yuansong Biotechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YSCH-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YSCH-01 overview
YSCH-01 is under development for the treatment of relapsed and refractory solid tumors, head and neck cancer, melanoma, cervical cancer, breast cancer, bladder cancer, ovarian cancer, recurrent glioblastoma, lung cancer, recurrent or metastatic head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, endometrial, fallopian tube and primary peritoneal cancer. The therapeutic candidate is a recombinant L-IFN adenovirus injection administered intratumorally and intracapsular injection.
Shanghai Yuansong Biotechnology overview
Shanghai Yuansong Biotechnology (Yuansong Biotechnology) operates in healthcare sector. Yuansong Biotechnology is headquartered in Shanghai, China.
For a complete picture of YSCH-01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
